EVMN Evommune13.57+1.21 (+9.8%)
Premarket Decliner
EVMN Evommune25.18+1.05+4.4%
Premarket:21.10-4.08 (-16.2%)
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria
Business WireMon, 29-Jun 8:30 AM
EVMN Evommune23.66-0.59 (-2.4%)
EVMN Evommune20.52+0.47 (+2.3%)
EVMN Evommune20.70+0.21 (+1.0%)